Gyre Therapeutics (GYRE) FCF Payout Ratio (2023)

Gyre Therapeutics (GYRE) posted quarterly FCF Payout Ratio of 0.27 for Q3 2023, down 84.29% quarter-over-quarter from 1.7 in Q2 2023.

Gyre Therapeutics (GYRE) FCF Payout Ratio (2023) Analysis & Trends

Gyre Therapeutics (GYRE) has reported FCF Payout Ratio for 1 consecutive years, with 0.27 the latest figure, recorded in Q3 2023.

In Q3 2023, FCF Payout Ratio changed N/A year-over-year to 0.27; the TTM figure through Sep 2023 stood at 0.22 (changed N/A YoY), while the FY2022 annual figure was 7.91, changed N/A from the prior year.
FCF Payout Ratio slipped to 0.27 in Q3 2023 per GYRE's latest filing, from 1.7 in the prior quarter.
Across five years, FCF Payout Ratio topped out at 1.7 in Q2 2023 and bottomed at 0.27 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.17
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.07
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Gyre Therapeutics	708.31 Mn	685.47 Mn	26.90 Mn	-

Download Data